🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 5 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 24/09/2018 | 179,43 | 182,50 | 179,43 | 182,17 | +1,16% | 1,71% | 706.300 |
| 21/09/2018 | 181,30 | 182,00 | 179,34 | 180,08 | -0,24% | 1,47% | 1.642.000 |
| 20/09/2018 | 177,39 | 181,38 | 177,39 | 180,52 | +2,22% | 2,25% | 784.800 |
| 19/09/2018 | 177,34 | 177,55 | 175,80 | 176,60 | -0,29% | 0,99% | 732.200 |
| 18/09/2018 | 175,88 | 178,46 | 174,23 | 177,12 | +0,75% | 2,41% | 964.900 |
| 17/09/2018 | 179,00 | 179,59 | 175,47 | 175,80 | -1,79% | 2,30% | 878.100 |
| 14/09/2018 | 180,51 | 181,88 | 177,77 | 179,01 | -0,47% | 2,28% | 847.300 |
| 13/09/2018 | 179,37 | 181,11 | 178,01 | 179,86 | +0,85% | 1,73% | 830.400 |
| 12/09/2018 | 179,46 | 179,98 | 177,09 | 178,34 | -0,15% | 1,61% | 860.800 |
| 11/09/2018 | 178,93 | 180,25 | 177,34 | 178,61 | -0,37% | 1,63% | 1.077.700 |
| 10/09/2018 | 180,00 | 180,57 | 177,98 | 179,28 | -0,11% | 1,44% | 797.500 |
| 07/09/2018 | 178,76 | 180,79 | 177,01 | 179,47 | -0,32% | 2,11% | 1.204.400 |
| 06/09/2018 | 182,51 | 183,32 | 178,20 | 180,05 | -1,72% | 2,81% | 890.700 |
| 05/09/2018 | 183,00 | 184,74 | 181,50 | 183,21 | -0,05% | 1,77% | 1.027.900 |
| 04/09/2018 | 183,23 | 184,59 | 181,67 | 183,31 | -0,59% | 1,59% | 1.371.100 |
| 31/08/2018 | 185,16 | 185,88 | 183,72 | 184,40 | -0,88% | 1,17% | 1.302.100 |
| 30/08/2018 | 185,00 | 186,19 | 184,37 | 186,03 | +0,63% | 0,98% | 968.900 |
| 29/08/2018 | 180,90 | 186,44 | 180,90 | 184,86 | +2,21% | 3,06% | 1.277.500 |
| 28/08/2018 | 180,36 | 182,22 | 178,83 | 180,87 | +0,86% | 1,88% | 1.257.600 |
| 27/08/2018 | 177,98 | 179,64 | 177,60 | 179,32 | +1,40% | 1,15% | 825.600 |
| 24/08/2018 | 176,45 | 177,28 | 175,10 | 176,84 | +0,47% | 1,24% | 905.200 |
| 23/08/2018 | 177,72 | 177,72 | 174,60 | 176,02 | -0,96% | 1,76% | 681.000 |
| 22/08/2018 | 176,81 | 178,23 | 176,02 | 177,72 | +0,49% | 1,25% | 616.400 |
| 21/08/2018 | 175,74 | 178,43 | 175,04 | 176,86 | +0,65% | 1,93% | 919.200 |
| 20/08/2018 | 176,62 | 176,83 | 173,62 | 175,71 | -0,21% | 1,82% | 946.700 |
| 17/08/2018 | 174,66 | 177,00 | 173,59 | 176,08 | +0,64% | 1,95% | 981.700 |
| 16/08/2018 | 174,18 | 176,28 | 173,09 | 174,96 | +1,13% | 1,83% | 732.500 |
| 15/08/2018 | 174,38 | 175,65 | 171,81 | 173,00 | -1,67% | 2,20% | 907.500 |
| 14/08/2018 | 175,31 | 177,30 | 175,31 | 175,93 | +0,50% | 1,14% | 566.700 |
| 13/08/2018 | 175,13 | 176,15 | 174,18 | 175,05 | +0,13% | 1,12% | 810.400 |